Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02006069 · ClinicalTrials.gov registry record · NA
MOre REsponse on Cardiac Resynchronization Therapy With MultiPoint Pacing
A NA study, sponsored by Abbott Medical Devices.
- Terminated
- Registry status
- NA
- Development phase
- 5,850
- Enrollment target
NCT02006069 is a NA study that was terminated before completion, run by Abbott Medical Devices. The registered enrollment target is 5,850 participants.
The verdict
NCT02006069, a NA study, was terminated before completion, sponsored by Abbott Medical Devices.
- TERMINATED
- Registry status
- NA
- Development phase
- 5,850 participants
- Enrollment target
Study Summary
The purpose of this Clinical investigation is to assess the impact of the Multi Point Pacing (MPP) feature at 12 months in the treatment of patients not responding to standard Cardiac Resynchronization Therapy (CRT) after 6 months.
Interventions
- DEVICE MPP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,850 participants |
| Start Date | 2013-12 |
| Est. Completion | 2021-05-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02006069
The ClinicalTrials.gov registry entry for NCT02006069 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 5,850 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MPP is the first listed.
NCT02006069 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02006069 about?
NCT02006069 is a clinical study titled "MOre REsponse on Cardiac Resynchronization Therapy With MultiPoint Pacing". The purpose of this Clinical investigation is to assess the impact of the Multi Point Pacing (MPP) feature at 12 months in the treatment of patients not responding to standard Cardiac Resynchronization Therapy (CRT) after 6 months.
What is the current status of trial NCT02006069?
This trial is currently terminated. It is a NA study. The enrollment target is 5,850 participants. The study started on 2013-12. Estimated completion is 2021-05-30.
What interventions are being tested in trial NCT02006069?
The interventions under investigation include: MPP (DEVICE).
Who is sponsoring clinical trial NCT02006069?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.